

Heme Malignancy Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Managers:

Stephanie Osorio
Judit Castellanos

Clinical Research Coordinators:

Kelsey McAbee
Harleen Mehrok
Alice Ting
Michael Kunicki
Georgina Alvarez-Diaz
Melisa Duvnjak

Data Coordinators:

Heather Franson
Neha Ashraf

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Front Line

ETCTN 10538 (suspended)

Venetoclax+ASTX727 (All oral therapy) for CMML, MDS/MPN with excess blasts

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: BCL-2 selective inhibitor

UCI 24-121

ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 0/5

Coord: TBD
Mechanism: cytidine deaminase inhibitor

Supportive Care

UCI 20-50

N-Acetylcysteine in MPN to Improve Disease Markers & Symptoms

Accrual 14/27

Coord: Kelsey McAbee
Mechanism: Mucolytic agent (cysteine and GSH precursor)

Newly diagnosed

UCI 24-121

ASTX030 in Subjects
w/Myeloid Neoplasm or in
Combo w/Venetoclax in
Subjects w/AML or MDS

Accrual: 0/5

Coord: TBD
Mechanism: cytidine
deaminase inhibitor

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Low-Risk

Molecularly-Driven

HSCT

High-Risk

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

High-Risk

UCI 22-151

LYT-200 in patients w/ R/R AML or high-risk MDS

Accrual: 6/8

Coord: Stephanie Osorio

Mechanism: Galectin-9 monoclonal antibody

UCI 23-113

Oral GLB-001 in patients w/ R/R AML or high-risk MDS

Accrual: 2/7

Coord: Stephanie Osorio

Mechanism: Selective molecular glue degrader

Low-Risk

UCI 21-239

IRAK 1/4 inhibitor, R289, in patients w/ refractory or resistant lower-risk MDS

Accrual: 1/5

Coord: Stephanie Osorio

Mechanism: IRAK1/4 inhibitor

Molecularly-Driven

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Intensive

ETCTN-10596 (SUSPENDED)

SNDX-5613 + Daunorubicin
 and Cytarabine in Newly
 Diagnosed Acute Myeloid
 Leukemia (NPM1
 Mutated/FLT3 Wildtype with
 Higher-Risk Features or
 MLL/KMT2A Rearranged)

Accrual: 0/5

Coord: Stephanie Osorio
 Mechanism: menin inhibitor

Non-Intensive

ETCTN-10630

Ladademstat in Combination with
 Venetoclax and Azacitidine in
 Patients with Post MDS
 Transformation to AML

Accrual: 2/7

Coord: Stephanie Osorio
 Mechanism: LSD1 inhibitor

UCI 24-121

ASTX030 in Subjects w/Myeloid
 Neoplasm or in Combo
 w/Venetoclax in Subjects
 w/AML or MDS

Accrual: 0/5

Coord: TBD
 Mechanism: cytidine
 deaminase inhibitor

KMT2A-r/NPM1-m

UCI 23-44

Venetoclax/Azacitidine v.s
 Venetoclax+ KO-530 v.s
 cytarabine/daunorubicin
 (7+3)+ KO-539 in AML

Accrual: 8/10

Coord: Stephanie Osorio
 Mechanism: menin
 inhibitor

FLT3 mutation

UCI 21-216

Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

Accrual: 2/5

Coord: Stephanie Osorio
 Mechanism: FLT3 inhibitor

Newly diagnosed

KMT2A-r/NPM1-m

UCI 25-20

Assessing Ziftomenib in
Combination with Either
Standard of Care Nonintensive
(Venetoclax+Azacitidine) or
Intensive (7+3) Therapy in
Patients with Untreated NPM1
Mutated or KMT2A
Rearranged AML

Accrual: 0/5

Coord: TBD

Mechanism: menin inhibitor

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

2nd Line+

UCI 23-113 (CLOSED TO ACCRUAL)

Oral GLB-001 in patients w/ R/R AML or high-risk MDS

Accrual: 2/7

Coord: Stephanie Osorio
Mechanism: Selective molecular glue degrader

UCI 22-81

HM43239 in patients w/ R/R AML

Accrual: 1/6

Coord: Stephanie Osorio
Mechanism: FLT3 inhibitor

UCI 22-151

LYT-200 in patients w/ R/R AML or high-risk MDS

Accrual: 6/8

Coord: Stephanie Osorio
Mechanism: Galectin-9 monoclonal antibody

UCI 24-48

DFP-10917+Venetoclax in R/R AML

Accrual: 4/5

Coord: Stephanie Osorio
Mechanism: Deoxycytidine nucleoside analogue (DNA synthesis inhibitor)

Open to Accrual

Low Accruing

Pending Activation/Suspended

Molecularly-Driven

≤1 Line Only

UCI 25-105

LYT-200 in patients w/ R/R AML or high-risk MDS

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: Galectin-9 monoclonal antibody

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Molecularly-Driven

KMT2A-r/NPM1-m

UCI 23-44

Venetoclax/Azacitidine v.s
Venetoclax+ KO-530 v.s
cytarabine/daunorubicin (7+3)+
KO-539 in AML

Accrual: 8/10

Coord: Stephanie Osorio
Mechanism: menin inhibitor

UCI 23-154

Ziftomenib combinations for
the KMT2A-rearranged/NPM1
mutant R/R AML

Accrual: 3/5

Coord: Stephanie Osorio
Mechanism: menin inhibitor

UCI 25-24

8-Chloro-Adenosine in
Combination with Decitabine and
Venetoclax in Patients with R/R
AML

Accrual: 0/5

Coord: TBD
Mechanism: RNA directed
nucleoside

Maintenance

High-Risk, HSCT

Salvage Therapy

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Ph+ only

EA9181

Steroids +TKI w/
chemotherapy or
Blinatumomab for BCR-ABL
positive adult patients

Accrual 14/25

Coord: Judit Castellanos
Mechanism: BiTE binding to
CD19 (on B-cell) and CD3 (on
T-cells) and PD-1 inhibitor

SWOG-21CTP-LEUK01

Phase II Trial of Asciminib,
Dasatinib, Prednisone, and
Blinatumomab for Participants
with Newly Diagnosed
Philadelphia Chromosome
Positive (PH+) Acute
Lymphoblastic Leukemia

Accrual: 0/5

Coord: Stephanie Osorio/Judit
Castellanos
Mechanism:

Ph- only

Age 5 to <30 years & High Risk ALL

UCI 21-14

Levocarnitine for Asparaginase
hepatotoxicity in ALL patients

Accrual: 0/5 (opened 11/3/23)

Coord: Judit Castellanos
Mechanism: Oxidative stress
reducer & inflammatory
modulator

Age ≥ 18 years & < 40 years,
CD22+ (≥ 20%)

A041501 (Suspended)

Addition of Inotuzumab
Ozogamicin to frontline
therapy in young adults (18-
39y/o)

Accrual: 10/15

Coord: Judit Castellanos
Mechanism: conjugated anti-
CD22 monoclonal antibody

UCI 25-104

subcutaneous blinatumomab
vs. intravenous blinatumomab
in newly diagnosed adults with
(Ph)- B cell precursor ALL

Accrual: 0/5

Coord: TBD
Mechanism: Bispecific T-cell
engager (BiTE)

Observational

UCI 21-236

Addressing the Hispanic
Cancer Disparity in B Cell
Acute Lymphoblastic
Leukemia
Accrual: NA

Coord: NA
Mechanism: Observational

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

CR w/ MRD+

CD22+ ($\geq 20\%$)**A041703 (SUSPENDED)**

Inotuzumab Ozogamicin followed by
Blinatumomab for ph- CD22-positive
newly diagnosed or R/R ALL patients

Accrual: 2/5 (only open for R/R)

Coord: Judit Castellanos
Mechanism: antibody-drug
conjugate combining a monoclonal
antibody targeting CD22 on B-
lymphoblast with the cytotoxic agents

Newly diagnosed

UCI 25-166

QTX-2101 in Newly Diagnosed Acute
Promyelocytic Leukemia

Accrual: 0/5

Coord: TBA

Mechanism: oral arsenic trioxide

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Newly diagnosed

UCI 23-189

Frontline Ruxolitinib with De-Intensified HLH-94 for Adults with Hemophagocytic Lymphohistiocytosis (HLH)

Accrual: 0/5

Coord: TBD

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

2nd Line+

UCI 23-167

Phase I- TERN-701 in patients
w/CML

Accrual: 2/5

Coord: Kelsey McAbee
Mechanism: STAMP inhibitor

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Newly Diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Post ASCT

UCI 23-49

ELRANATAMAB (PF-06863135) +
 DARATUMUMAB + LENALIDOMIDE
 VERSUS DARATUMUMAB +
 LENALIDOMIDE + DEXAMETHASONE
 IN TRANSPLANT-INELIGIBLE
 PARTICIPANTS WITH NEWLY-
 DIAGNOSED MULTIPLE MYELOMA
 Accrual: 0/5

Coord: TBD
 Mechanism: IgG1 kappa (IgG1κ) MAB

UCI 24-170

Intravenous Gammagard Liquid
 (Immune Globulin Infusion, 10%) for
 Primary Infection Prophylaxis
 Compared With Secondary Infection
 Prophylaxis in Adult Subjects With
 Multiple Myeloma Receiving B-Cell
 Maturation Antigen×CD3-Directed
 Bispecific Antibody Therapy
 Accrual: 0/8

Coord: TBD
 Mechanism: IVIG

Front Line

Bispecific

UCI 23-158 (SUSPENDED)

Phase I/II Study of Linvoseltamab
 (Anti-BCMA X Anti-CD3 Bispecific
 Antibody) in Previously Untreated
 Patients with Symptomatic Multiple
 Myeloma
 Accrual: 1/6 (opened 3/29/24)

Coord: Alice Ting
 Mechanism: Bispecific antibody
 (BCMA x CD3)

High-Risk

ETCTN 10612

A Randomized Phase 2 Study of
 Daratumumab-Selinexor-Velcade-
 Dexamethasone (Dara-SVD) for
 High-Risk Newly Diagnosed
 Multiple Myeloma

Accrual: 7/8 (opened 4/25/24)

Coord: Alice Ting
 Mechanism: selective inhibitor of
 nuclear export

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Molecularly-Driven

3rd Line+

CAR-T

UCI 24-02 (SUSPENDED)

Descartes-15 in R/R MM

Accrual: 3/5

Coord: Mike Kunicki

Mechanism: CAR-T, BCMA

ALLIANCE-A062102

Iberdomide Maintenance
Therapy Following Idecabtagene
Vicleucel CAR-T in R/R MM

Accrual: 0/5

Coord: Judit Castellanos

Mechanism: cereblon (CRBN)
modulating agent

UCI 25-116

ANTITUMOR ACTIVITY OF
SIM0500, IN PARTICIPANTS
WITH R/R MULTIPLE MYELOMA

Accrual: 0/5

Coord: TBD

Mechanism: GPRC5D-BCMA-
CD3 TRISPECIFIC ANTIBODY

UCI 24-170

Intravenous Gammagard Liquid
(Immune Globulin Infusion, 10%)
for Primary Infection Prophylaxis
Compared With Secondary
Infection Prophylaxis in Adult
Subjects With Multiple Myeloma
Receiving B-Cell Maturation
Antigen×CD3-Directed Bispecific
Antibody Therapy

Accrual: 0/8

Coord: TBD

Mechanism: IVIG

UCI 25-62

EXPANDED ACCESS PROTOCOL
(EAP) FOR SUBJECTS RECEIVING
IDECABTAGENE VICLEUCEL
THAT IS NONCONFORMING
FOR COMMERCIAL RELEASE

Accrual: 0/5

Coord: TBD

Mechanism: CAR-T

2nd Line+

Maintenance

Newly diagnosed

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

S1918 (SUSPENDED)

R-miniCHOP w/ or w/o oral Azacitidine
in patients 75 y/o or older

Accrual: 5/10

Coord: Melisa Duvnjak

Mechanism: Oral hypomethylating
agent

UCI 23-19

PhIII Odronextamab Comb w/CHOP vs
Rituximab Comb w/CHOP

Accrual: 0/5

Coord: Melisa D.

Mechanism: Anti-CD20 x Anti-CD3
bispecific antibody

UCI 24-22

Loncastuximab Tesirine and Rituximab
(Lonca-R) Followed by DA-EPOCH-R in
Previously Untreated High-risk Diffuse
Large B-cell Lymphoma

Accrual: 0/5

Coord: TBD

Mechanism: monoclonal IgG1 kappa
antibody/EPOCH regimen

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Primary Relapsed/Refractory

Secondary Relapsed/Refractory

UCI 20-126 (suspended)

CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

Accrual: 7/10

Coord: Michael K.

Mechanism: anti-CD19 **CHIMERIC
ANTIGEN RECEPTOR**

UCI 21-217

safety and effectiveness of tafasitamab in combination with lenalidomide in US patients with relapsed or refractory diffuse large B-cell lymphoma with a focus on racial and ethnic minority patients.

Accrual: 1/6

Coord: Alice Ting

Mechanism: CD19 antibody

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

Tertiary Relapsed/Refractory

S2114

Consolidation therapy
following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Michael Kunicki
Mechanism: bite/mab

2+ Lines

UCI 24-12

Study to Evaluate the BTK Degradar,
ABBV-101, in Participants With B-cell
Malignancies

Accrual: 1/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101
monotherapy

UCI 25-53

JNJ-90014496, an Autologous
CD19/CD20 Bi-specific CAR-T Cell
Therapy in Adult Participants with B-cell
Non-Hodgkin Lymphoma

Accrual: 0/5

Coord: TBD
Mechanism: Bi-specific CAR T

UCI 25-04

A Phase I/II, multicenter study
evaluating point-of-care manufactured
GLPG5101 (19CP02) in subjects with
R/R B-cell non-Hodgkin lymphoma
(CP0201NHL)

Accrual: 0/5

Coord: TBD
Mechanism: FMC63 anti-CD19 CAR T

UCI 23-114

Safety and Efficacy of IMPT-314, a
CD19/20 Bispecific Chimeric Antigen
Receptor (CAR) T Cell Therapy in B-
cell NHL

Accrual: 4/7

Coord: Judit Castellanos
Mechanism: CD19/20 bispecific CAR

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Low Grade

SWOG 2308

MOSUNETUZUMAB VS.
RITUXIMAB FOR LOW TUMOR
BURDEN FOLLICULAR
LYMPHOMA

Accrual: 0/5

Coord: Melisa D.
Mechanism: Anti-CD20 IgG1
kappa antibody

≥75 years

S1918 (SUSPENDED)

R-miniCHOP w/ or w/o oral
Azacitidine in patients 75 y/o or
older

Accrual: 5/10

Coord: Melisa Duvnjak
Mechanism: Oral
hypomethylating agent

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

2nd Line+

UCI 22-134

Oral AS-1763 in patients w/
previously treated CLL/SLL or
NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor

3rd Line+

UCI 24-12

BTK Degradar ABBV-101 in
Pts w/ B-cell Malignancies

Accrual: 1/5

Coord: Kelsey McAbee
Mechanism: BTK degrader

Consolidation

S2114

Consolidation therapy
following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Michael Kunicki
Mechanism: bite/mab

Maintenance

UCI 21-95

Acalabrutinib Maintenance
Following Cellular Therapy for
LBCL Patients at High Risk for
Relapse

Accrual: 0/5

Coord: TBD
Mechanism: BTK

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Cell Therapy

UCI 20-126 (suspended)

CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

Accrual: 7/10

Coord: Michael K.
Mechanism: anti-CD19 CAR-T

UCI 23-114

Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL

Accrual: 4/7

Coord: Michael Kunicki
Mechanism: CD19/20 bispecific CAR

UCI 25-04

PhI/II, multicenter study evaluating GLPG5101 (19CP02) in pts w/ R/R B-cell NHL (CP0201NHL)

Accrual: 0/5

Coord: TBD
Mechanism: FMC63 anti-CD19

UCI 25-63

EAP for Lisocabtagene Maraleucel (liso-cel) that is Nonconforming for Commercial Release

Accrual: 0/5

Coord: TBD
Mechanism: anti-CD19 CAR T

UCI 25-70

Ph III of LYL314 in 2L for R/R B-Cell NHL

Accrual: 0/0

Coord: Michael K.
Mechanism: CD19/20 CAR

UCI 25-53

JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with B-cell Non-Hodgkin Lymphoma

Accrual: 0/5

Coord: TBD
Mechanism: Bi-specific CAR T

Relapsed/Refractory

Open to Accrual

Low Accruing

Pending Activation/Suspended

Cell Therapy

Molecularly-Driven

3rd Line+

UCI 22-134

Oral AS-1763 in patients w/
previously treated CLL/SLL or NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor for both
wild-typ and C481S-mutant type

2+ Lines

UCI 24-12

Study to Evaluate the BTK
Degradar, ABBV-101, in
Participants With B-cell
Malignancies

Accrual: 1/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-
101 monotherapy

UCI 25-04

A Phase I/II, multicenter study
evaluating point-of-care
manufactured GLPG5101 (19CP02)
in subjects with R/R B-cell non-
Hodgkin lymphoma (CP0201NHL)

Accrual: 0/5

Coord: TBD
Mechanism: FMC63 anti-CD19 CAR
T

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

EBV+

Molecularly-Driven

2 + Lines

UCI 24-12

Study to Evaluate the BTK Degradar, ABBV-101, in Participants With B-cell Malignancies

Accrual: 1/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101 monotherapy

UCI 25-04

A Phase I/II, multicenter study evaluating point-of-care manufactured GLPG5101 (19CP02) in subjects with R/R B-cell non-Hodgkin lymphoma (CP0201-NHL)

Accrual: 0/5

Coord: TBD
Mechanism: FMC63 anti-CD19 CAR T

3rd Line+UCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

High-Risk

S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Accrual: 4/10

Coord: Kelsey McAbee
Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

Front Line

UCI 23-156

Sonrotoclax (BGB-11417) + Zanubrutinib (BGB-3111) v.s. Venetoclax +Obinutuzumab

Accrual: 3/7

Coord: Kelsey McAbee
Mechanism: BTK + BCL2 inhibition

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

3rd Line+**UCI 22-134**

Oral AS-1763 in patients w/
previously treated CLL/SLL or NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor for both
wild-typ and C481S-mutant type

UCI 24-12

Study to Evaluate the BTK Degradar,
ABBV-101, in Participants With B-cell
Malignancies

Accrual: 1/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-
101 monotherapy

2nd Line+**UCI 24-190**

A Phase III Study of Sonrotoclax Plus
Anti-CD20 Antibody Therapies Versus
Venetoclax + Rituximab in Patients With
R/R CLL/SLL

Accrual: 0/7

Coord: Stephanie Osorio/Judit
Castellanos
Mechanism: Anti-CD20 Antibody

UCI 24-32

Epcoritamab as Consolidation Therapy
for High-risk Patients with Chronic
Lymphocytic Leukemia on Bruton
Tyrosine Kinase Inhibitor

Accrual: 0/24

Coord: Stephanie Osorio/Judit
Castellanos
Mechanism: BTKi/Epcoritamab

UCI 25-04

A Phase I/II, multicenter study
evaluating point-of-care manufactured
GLPG5101 (19CP02) in subjects with
R/R B-cell non-Hodgkin lymphoma
(CP0201NHL)

Accrual: 0/5

Coord: TBD
Mechanism: FMC63 anti-CD19 CAR T

UCI 25-148

IgPro20 in Subjects with Chronic
Lymphocytic Leukemia / Small
Lymphocytic Lymphoma and
Secondary Hypogammaglobulinemia
Experiencing Severe or Recurrent
Infections

Accrual: 0/5

Coord: TBD
Mechanism: protein liquid preparation
of polyvalent human IgG

Newly diagnosed

COG ANHL1931

Nivolumab + chemo-immunotherapy

Accrual: 2/5

Coord: Melisa Duvnjak

Mechanism: PD1 inhibitor

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

Consolidation

S2114

Consolidation therapy following
CD19 CAR T-cell tx

Accrual: 0/6

Coord: Michael Kunicki
Mechanism: bite/mab

2+ Lines

UCI 24-12

Study to Evaluate the BTK
Degradar, ABBV-101, in
Participants With B-cell
Malignancies

Accrual: 1/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-
101 monotherapy

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

Cell Therapy

UCI 23-114

Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL
Accrual: 4/7

Coord: Judit Castellanos
Mechanism: CD19/20 bispecific CAR

UCI 25-04

A Phase I/II, multicenter study evaluating point-of-care manufactured GLPG5101 (19CP02) in subjects with R/R B-cell non-Hodgkin lymphoma (CP0201NHL)

Accrual: 0/5

Coord: TBD
Mechanism: FMC63 anti-CD19 CAR T

2+ Lines

UCI 24-12

Study to Evaluate the BTK Degradator, ABBV-101, in Participants With B-cell Malignancies

Accrual: 1/5

Coord: Kelsey McAbee
Mechanism: BTK inhibitor/f ABBV-101 monotherapy

3rd line+

UCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 4/9

Coord: Kelsey McAbee
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

UCI 24-174

Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 0/5

Coord: Judit Catellanos
Mechanism: ASCT

UCI 21-95

Acalabrutinib Maintenance Following Cellular Therapy for LBCL Patients at High Risk for Relapse

Accrual: 0/5

Coord: TBD
Mechanism: BTK

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

2nd Line+

UCI 21-99

ONO-4685 given as monotherapy

Accrual: 4/10

Coord: TBD

Mechanism: CD3-bispecific antibody targeting PD-1

UCI 25-74

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase I/II Study to Evaluate the Safety and Efficacy of DR-01 in Subjects with LGLL or Cytotoxic Lymphomas

Accrual: 0/5

Coord: TBD

Mechanism: non fucosylated human IgG1 anti CD94 antibody

UCI 24-188

PHASE 2 STUDY OF PTX-100 MONOTHERAPY IN PATIENTS WITH R/R CUTANEOUS T-CELL LYMPHOMA

Accrual: 0/5

Coord: TBD

Mechanism: GGTase 1 inhibitor

UCI 25-142

Study of KK2223 in Participants with Relapsed or Refractory T-cell Non-Hodgkin Lymphoma

Accrual: 0/5

Coord: TBD

Mechanism: FMC63 anti-CD19 CAR T

Relapsed/Refractory

1st Line+

UCI 25-142

Study of KK2223 in Participants with Relapsed or Refractory T-cell Non-Hodgkin Lymphoma

Accrual: 0/5

Coord: TBD

Mechanism: naked CD4 antibody

3rd Line+

UCI 21-99

ONO-4685 given as monotherapy

Accrual: 4/10

Coord: TBD

Mechanism: CD3-bispecific antibody targeting PD-1

UCI 24-174

Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 0/5

Coord: Judit Catellanos

Mechanism: ASCT

ECOG EA4232

Phase III Study to Evaluate Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Accrual: 0/5

Coord: TBD

Mechanism: ASCT

Newly Diagnosed

UCI 22-18

Investigation of MRD in patients with treatment-naïve systemic T cell lymphoma treated with a brentuximab-containing regimen

Accrual: 0/5

Coord: TBD

Mechanism:



UCI 25-74

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase I/II Study to Evaluate the Safety and Efficacy of DR-01 in Subjects with LGLL or Cytotoxic Lymphomas

Accrual: 0/5

Coord: TBD

Mechanism: non fucosylated human IgG1 anti CD94 antibody

Newly Diagnosed

COG-AHOD2131

Standard Therapy with
Immuno-oncology Therapy
for Newly Diagnosed Stage I
and II Classical Hodgkin
Lymphoma

Accrual: 1/5

Coord: Judit Castellanos/
Stephanie Osorio
Mechanism:

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

 ≥ 1 Line

UCI 25-21

Pembrolizumab and GVD with
ctDNA-guided Consolidation
in Patients with Relapsed or
Refractory Classic Hodgkin

Lymphoma

Accrual: 1/5

Coord: TBD

Mechanism: PD-1 inhibitor

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

Basket study

CAR-T Products

Allogeneic CAR-T

NHL

UCI 20-126 (suspended)

CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

Accrual: 7/10

Coord: Michael K.
Mechanism: anti-CD19 CAR-T

Open to Accrual

Low Accruing

Pending Activation/Suspended

Autologous CAR-T

NHL

UCI 23-114

Safety & Efficacy of LYL314, a CD19/20 Bispecific CAR-T for R/R B-Cell NHL

Accrual: 4/7

Coord: Michael K.
Mechanism: CD19/20 CAR

UCI 25-70

Ph III of LYL314 in 2L for R/R B-Cell NHL

Accrual: 0/0

Coord: Michael K.
Mechanism: CD19/20 CAR

UCI 25-53

Ph Ib/II of JNJ-90014496, an auto CD19/CD20 Bi-Specific CAR-T

Accrual: 0/0

Coord: TBD

UCI 25-04

Ph I/II, multicenter study evaluating GLPG5101 (19CP02) in pts w/ R/R B-cell NHL (CP0201NHL)

Accrual: 0/5

Coord: TBD
Mechanism: FMC63 anti-CD19 CAR T

UCI 25-63

EAP for Lisocabtagene Maraleucel (liso-cel) that is Nonconforming for Commercial Release

Accrual: 0/5

Coord: TBD
Mechanism: anti-CD19 CAR T

MM

UCI 24-02

Descartes-15 in R/R MM

Accrual: 3/5

Coord: Mike K.
Mechanism: CAR-T, BCMA

UCI 25-63

EAP for Vicleucel (ide-cel) that is Nonconforming for Commercial Release

Accrual: 0/5

Coord: TBD
Mechanism: anti-CD19 CAR T

Other

UCI 24-152

NXC-201 for the Treatment of Patients w/ R/R AL Amyloidosis

Accrual: 0/10

Coord: TBD
Mechanism: anti-CD3 CAR T

Supportive Care

Autologous

UCI 23-193

CTO1681 for the Prevention & Treatment of CRS in pts w/ DLBCL receiving CAR-T Therapy
Accrual: 1/5

Coord: Alice Ting
Mechanism: PGE2 & PGI2 agonist

S2114

Consolidation Therapy Following CD19 CAR-T for R/R Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Accrual: 0/6

Coord: Michael Kunicki
Mechanism: BiTE/mAb

Alliance-A062102

Iberdomide Maintenance Therapy Following Ide-Cel CAR-T in R/R Multiple Myeloma

Accrual: 0/5

Coord: TBD
Mechanism: Cereblon (CRBN) modulating agent

Allogeneic

UCI 21-90

Risk-ADAPTEd conditioning regimen for AHSCT

Accrual: 24/48

Coord: Heme CRCs

UCI 22-188

Prospective evaluation of CMV-TCIP directed Letemovir ppv after AHCT

Accrual: 13/50

Coord: Heme CRCs

UCI 24-131

Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Accrual: 0/5

Coord: Mike C.
Mechanism: (CSF1R)

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

LTFU**UCI 21-184**

Long-term safety of CAR-T
inpatient w/ heme malignancies

Accrual: 5/5

Coord: Michael Kunicki

UCI 24-31

Long-Term Follow-up Protocol for
Subjects Treated With Gene-
Modified T Cells

Accrual: 0/5

Coord: TBD

UCI 25-126

A long-term follow-up study for
patients treated with Galapagos CAR
T-cell therapies

Accrual: 0/5

Coord: TBD

Mechanism: N/A

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Other

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 14-03

Role of Inflammation in the Pathogenesis of Myeloproliferative Neoplasm

UCI 24-110

HaploDonor-QoL: Donor Health-Related Quality-of-Life and Physician Decision-Making in the Context of Haploidentical Hematopoietic Stem Cell Transplantation

UCI 15-65

Effect of candidate blood cancer therapies on normal human lymphocytes

UCI 14-89

Hematologic Malignancies Biorepository for human research

UCI 22-194

A Retrospective analysis of L-carnitine for Treatment and/or Prevention of L-Asparaginase Hepatotoxicity during Induction or Salvage Chemotherapy for Hematologic Malignancies